Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg

BACKGROUND: Two different enzyme preparations, agalsidase alfa (Replagal(TM), Shire) and beta (Fabrazyme(TM), Genzyme), are registered for treatment of Fabry disease. We compared the efficacy of and tolerability towards the two agalsidase preparations administered at identical protein dose in a rand...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Vedder, Anouk C., Linthorst, Gabor E., Houge, Gunnar, Groener, Johannna E.M., Ormel, Els E., Bouma, Berto J., Aerts, Johannes M.F.G., Hirth, Asle, Hollak, Carla E.M.
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2007
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC1913555/
https://ncbi.nlm.nih.gov/pubmed/17622343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0000598
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki